MedTrace Logo

Feasibility of Using Contrast Enhanced Voiding Urosonography (CeVUS) During Urodynamic Studies

NCT04170413 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2020-11-04

No results posted yet for this study

Summary

The investigators will assess the feasibility of replacing fluoroscopy/iodinated contrast with ultrasound/sulfur hexafluoride lipid-type A microspheres during routine urodynamic studies.

Conditions

  • Neurogenic Bladder

Interventions

DRUG

CeVUS

Contrast enhanced voiding urosonography

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Reza Daugherty, MD · University of Virginia Health System

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2020-11-02
Completion
2020-11-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04170413 on ClinicalTrials.gov